Interaction of imatinib mesilate with human P-glycoprotein.
about
Kinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitorsRole of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitorsNilotinib counteracts P-glycoprotein-mediated multidrug resistance and synergizes the antitumoral effect of doxorubicin in soft tissue sarcomasClinical Implications of P-Glycoprotein Modulation in Drug-Drug Interactions.Small molecule kinase inhibitors approved by the FDA from 2000 to 2011: a systematic review of preclinical ADME data.A dual-fluorescence high-throughput cell line system for probing multidrug resistance.Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.Environmental and genetic factors affecting transport of imatinib by OATP1A2Imatinib and Panax ginseng: a potential interaction resulting in liver toxicity.ABCB1 regulation through LRPPRC is influenced by the methylation status of the GC -100 box in its promoter.A neuropharmacokinetic assessment of bafetinib, a second generation dual BCR-Abl/Lyn tyrosine kinase inhibitor, in patients with recurrent high-grade gliomasWnt/β-catenin pathway regulates ABCB1 transcription in chronic myeloid leukemia.Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib.Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing programOncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor.Synthesis and characterization of a BODIPY conjugate of the BCR-ABL kinase inhibitor Tasigna (nilotinib): evidence for transport of Tasigna and its fluorescent derivative by ABC drug transporters.Pharmacophore-based discovery of ligands for drug transporters.Interaction of innovative small molecule drugs used for cancer therapy with drug transporters.In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib.Contribution of tumoral and host solute carriers to clinical drug response.Influence of the dual ABCB1 and ABCG2 inhibitor tariquidar on the disposition of oral imatinib in mice.Drug-drug interactions with imatinib: An observational study.Interactions of pluronic block copolymers on P-gp efflux activity: experience with HIV-1 protease inhibitors.Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological propertiesTherapeutic drug monitoring for imatinib: Current status and Indian experience.ABCB1 haplotypes are associated with P-gp activity and affect a major molecular response in chronic myeloid leukemia patients treated with a standard dose of imatinib.Effects of herbal products on the metabolism and transport of anticancer agents.Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?Nilotinib: a novel, selective tyrosine kinase inhibitor.Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib.A systematic analysis of physicochemical and ADME properties of all small molecule kinase inhibitors approved by US FDA from January 2001 to October 2015.Suppression of carboxylesterases by imatinib mediated by the down-regulation of pregnane X receptor.Pharmacogenetics of drug transporters in modulating imatinib disposition and treatment outcomes in chronic myeloid leukemia & gastrointestinal stromal tumor patients.Characterization of a multidrug-resistant chronic myeloid leukemia cell line presenting multiple resistance mechanisms.Renal Drug Transporters and Drug Interactions.Influence of the multidrug transporter P-glycoprotein on the intracellular pharmacokinetics of vandetanib.Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells.Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways.Calcein assay: a high-throughput method to assess P-gp inhibition.Pharmacokinetic impact of SLCO1A2 polymorphisms on imatinib disposition in patients with chronic myeloid leukemia.
P2860
Q26849792-FF41E351-936D-4AEF-9713-EF23ADB2EC7FQ28236180-CEED47D2-FE87-4E8C-B8F4-50C46C194C55Q28483929-A9A70E13-FEF2-4E52-A439-F202D9E391A4Q30234940-FF6757CB-DA94-4032-8188-AEE10106FFEAQ30664269-E132F877-DEC6-468F-A6D3-964F5C89F434Q33472881-1C7375CF-2F4B-401E-AA10-19BB6A275E07Q33566582-EDB1C234-F698-41F8-BEA3-7BCD791420C6Q33878471-97F8E4D7-01C7-487C-987C-B7E35F58687EQ34106390-B7F951E7-099F-4F9C-973F-FAF6F9452491Q34183433-B16B1D4C-A963-4D70-B09D-9189F2999442Q34231554-07490FA2-AD3C-490C-BDB7-1F0A9364E65CQ34348134-D5253F7D-0088-4645-BBAD-9C0ED7CD33EDQ34636081-58656419-5CBD-4703-BD92-7B033F22F035Q35005309-5EC532EB-BE25-4AAB-8A67-C10CC1408C8AQ35036482-B59AA6C3-A5E2-482D-B066-A38E6589D2AEQ35141800-3100D366-CE3E-418C-8498-E2D686C90618Q35594214-09FCD616-E8DD-4728-8D3D-DEF9EA390BFFQ35708124-70454935-46C8-483F-8B0B-2C1310A8B35DQ35819214-739F01F6-2028-4E74-AD86-44D40CE4BF2DQ35946876-F1F32688-6D63-4ECC-A807-559B671E1A2EQ37281354-874AACED-8DB9-4187-8763-91817B33899EQ37328934-2B90DBB1-DCA6-4782-9B62-946854FCEF07Q37394989-71379C6A-7535-4662-B819-4BE2B0A9EEA6Q37447522-A734A05D-D2EE-4B15-98D6-F04912F69979Q37517632-A4DC26F6-74B0-48A0-A16B-395326C8A585Q37652283-8D43ED84-B2AF-4260-B609-C80F3F26696EQ37779320-A959F0EE-3299-4106-9558-D26568309B44Q37853578-1CD81E6E-A565-4CB7-BF3A-C288CF24B7C9Q37855073-E9F507EA-9CB3-4C54-93E1-1655B6EF80CEQ38150978-3A1A9455-BFC0-47A9-936C-7767388D5844Q38763312-DEA75B67-F64E-4035-9908-F0E12260B1A1Q38995804-6FB30947-4D75-458F-B5CB-E9AB5A25ED7AQ38996487-3EDB6B90-0BA9-41BF-99AD-E9C7DF53599DQ39121828-74A56119-CAFB-4562-BE67-17D37E9D551FQ39140289-1A093F25-B456-4AE1-B32D-B2340BDD962CQ39187613-B131AF81-DF44-4A1E-82FA-BB57E57E2687Q39440567-A5DBBC0E-5B20-43D7-A676-8112DED22475Q39515384-89E33165-9F98-455C-AC04-E3266F681E23Q39527868-B69150C6-4D87-46C3-95DF-A8961743ED3AQ39531941-3D40B11E-E9B5-4B89-B004-FCED2B0EFA70
P2860
Interaction of imatinib mesilate with human P-glycoprotein.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Interaction of imatinib mesilate with human P-glycoprotein.
@en
type
label
Interaction of imatinib mesilate with human P-glycoprotein.
@en
prefLabel
Interaction of imatinib mesilate with human P-glycoprotein.
@en
P2093
P356
P1476
Interaction of imatinib mesilate with human P-glycoprotein.
@en
P2093
Akinobu Hamada
Hideto Miyano
Hideyuki Saito
Hiroshi Watanabe
P304
P356
10.1124/JPET.103.055574
P407
P577
2003-09-15T00:00:00Z